by Dr. Ed Weber | Jan 21, 2020 | PCa Commentary
Something big is emerging in the management of men with metastatic (often heavily pre-treated) castration-resistant prostate cancer. A potentially new entry into the regimens of standard-of-care i.e., treatment of men with BRCA 1/2 and ATM mutations with PARP... by Dr. Ed Weber | Dec 4, 2019 | PCa Commentary
Adjuvant radiation and ADT following prostatectomy for high-risk prostate cancer:RTOG Trial 9601, Shipley et al., JCO, 2017 Jan. The findings from this randomized Phase III trial supported the current standard of care for this situation. It compared two treatments... by Dr. Ed Weber | Oct 2, 2019 | PCa Commentary
The suggestion that a few (usually 3 – 5, i.e., ‘oligometastatic’) lesions at the time of biochemical failure after primary treatment might represent an indolent disease state with limited potential for additional spread. This hypothesis was first made in 1995... by Dr. Ed Weber | Oct 2, 2019 | PCa Commentary
* The first study of active surveillance (AS) was started in 1996 at the University of Toronto byDr. Lawrence Klotz. It was first reported in the literature in 2002. In the ensuing 20 years AS has become increasingly accepted as a management approach to biopsy... by Dr. Ed Weber | Sep 5, 2019 | PCa Commentary
Radium-223 combined with Lupron demonstrated a median 3.6 month extension of overall survival, compared to the placebo (14.9 v 11.3 months). This was the outcome of a 928 man randomized trial (ASYMPCA) in asymptomatic or mildly symptomatic men with... by Dr. Ed Weber | Aug 29, 2019 | PCa Commentary
The Natural History of Prostate Cancer and the Prognostic Utility of PSA Doubling Time. We are indebted to UroToday for making available online the informative presentation at ASCO 2019 by Dr. Catherine Marshall: “Outcomes of Men with Recurrent MO [metastasis...